Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

61. Association between incidence of atrial fibrillation and duration of cardiopulmonary bypass in coronary artery bypass graft surgery (CABG): a cohort study

Association between incidence of atrial fibrillation and duration of cardiopulmonary bypass in coronary artery bypass graft surgery (CABG): a cohort study 29881524 2018 11 14 2008-5842 10 4 2018 Apr Electronic physician Electron Physician Association between incidence of atrial fibrillation and duration of cardiopulmonary bypass in coronary artery bypass graft surgery (CABG): a cohort study. 6624-6630 10.19082/6624 Open heart surgery is one of the most common and valuable treatment methods (...) for cardiovascular diseases, a common side effect of which is atrial fibrillation that occurs due to various reasons. To determine the relationship between incidence of atrial fibrillation (AF) and duration of cardiopulmonary bypass (CPB) in patients after open heart surgery. The present retrospective cohort study was conducted on 330 patients in Farshchian Heart Center through census. The required data were collected from medical records of the patients undergoing coronary bypass surgery using data collection

Electronic physician2018 Full Text: Link to full Text with Trip Pro

62. Alternative drug may prevent atrial fibrillation following heart surgery

Alternative drug may prevent atrial fibrillation following heart surgery NIHR DC | Signal - Alternative drug may prevent atrial fibrillation following heart surgery Dissemination Centre Discover Portal NIHR DC Discover Alternative drug may prevent atrial fibrillation following heart surgery Published on 12 December 2017 After heart surgery around a third of people have atrial fibrillation, an abnormal heart rhythm, which impedes their recovery and lengthens hospital stay. Colchicine treatment (...) could reduce this complication by about a third. About 11 people would need this treatment to prevent one of them developing atrial fibrillation. Using amiodarone, an alternative drug commonly used in this situation, other research shows that about seven people would be treated to prevent one person suffering fibrillation. Colchicine is a drug licensed for the treatment of gout that combines both anti-inflammatory and heart rate control properties. As an older drug, it might be a cheaper alternative

NIHR Dissemination Centre2018

63. Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation

Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation NIHR DC | Signal - Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 In people with atrial fibrillation needing (...) anticoagulant treatment, deaths were fewer in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique

NIHR Dissemination Centre2018

64. Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation

Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation NIHR DC | Signal - Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Published on 18 July 2017 General practice software that generated screen reminders for patients with atrial fibrillation did not increase (...) the proportion taking oral anticoagulants appropriately by six months. This NIHR-funded trial included GPs in 47 surgeries in England and found that at the start only 63% of eligible patients with atrial fibrillation were being prescribed anticoagulants. Six months later the rate had increased to 66% in intervention practices and 64% in those following usual practice, a non-significant difference between the groups. Use of the software was associated with increased diagnosis of transient ischemic attack

NIHR Dissemination Centre2018

65. Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits

Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits NIHR DC | Signal - Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Published on 27 September 2016 When treating atrial fibrillation, short-term (...) use of rhythm control drugs after catheter ablation reduced the risk of abnormal heart rhythms in the three months after the procedure. They were of no benefit in preventing recurrence of atrial fibrillation in the longer term. Atrial fibrillation is a common abnormal heart rhythm that carries a high risk of stroke. Catheter ablation can be used to destroy the electrical pathways in the heart muscle that cause the abnormal rhythm, but recurrence is common. Several factors could influence

NIHR Dissemination Centre2018

66. Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis

Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis 29476748 2018 03 30 1555-7162 2018 Feb 21 The American journal of medicine Am. J. Med. Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis. S0002-9343(18)30109-8 10.1016/j.amjmed.2018.01.032 Although postoperative atrial fibrillation is common after noncardiac surgery, there is a paucity of data regarding prophylaxis. We sought to determine whether pharmacologic prophylaxis (...) reduces the incidence of postoperative atrial fibrillation after noncardiac surgery. We performed an electronic search of Ovid MEDLINE, the Cochrane central register of controlled trials database, and SCOPUS from inception to September 7, 2016 and included prospective randomized studies in which patients in sinus rhythm underwent noncardiac surgery and examined the incidence of postoperative atrial fibrillation as well as secondary safety outcomes. Twenty-one studies including 11,608 patients were

EvidenceUpdates2018

67. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation 29579168 2018 03 26 1522-9645 2018 Mar 20 European heart journal Eur. Heart J. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. 10.1093/eurheartj/ehy176 It is recommended to perform atrial fibrillation ablation with continuous anticoagulation. Continuous apixaban has not been tested. We compared continuous apixaban (5 mg b.i.d.) to vitamin K antagonists (VKA (...) , international normalized ratio 2-3) in atrial fibrillation patients at risk of stroke a prospective, open, multi-centre study with blinded outcome assessment. Primary outcome was a composite of death, stroke, or bleeding (Bleeding Academic Research Consortium 2-5). A high-resolution brain magnetic resonance imaging (MRI) sub-study quantified acute brain lesions. Cognitive function was assessed by Montreal Cognitive Assessment (MoCA) at baseline and at end of follow-up. Overall, 674 patients (median age 64 years, 33% female

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

68. Meta-Analysis of Antithrombotic Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention

Meta-Analysis of Antithrombotic Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention 29548674 2018 03 17 1879-1913 2018 Feb 14 The American journal of cardiology Am. J. Cardiol. Meta-Analysis of Antithrombotic Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. S0002-9149(18)30178-4 10.1016/j.amjcard.2018.01.036 Current clinical practice prefers oral anticoagulation (OAC) plus dual antiplatelet therapy (DAPT) in atrial fibrillation (AF) after percutaneous (...) of myocardial infarction (MI) in RCTs restricted analysis (RR 1.18, 95% CI 0.89 to 1.56, p = 0.24); however, analysis of OSs showed 76% higher risk of MI with OAC plus SAP. In conclusion, in patients with AF after PCI, RCTs recommend OAC plus SAP for better safety and equal efficacy compared with OAC plus DAPT. These findings oppose the results of OSs that showed similar safety and reduced risk of MI with OAC plus DAPT. Copyright © 2018 Elsevier Inc. All rights reserved. Khan Safi U SU Guthrie Health System/Robert

EvidenceUpdates2018

69. Digoxin and Mortality in Patients With Atrial Fibrillation

Digoxin and Mortality in Patients With Atrial Fibrillation 29519345 2018 03 09 1558-3597 71 10 2018 Mar 13 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Digoxin and Mortality in Patients With Atrial Fibrillation. 1063-1074 S0735-1097(18)30103-7 10.1016/j.jacc.2017.12.060 Digoxin is widely used in patients with atrial fibrillation (AF). The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and (...) ); these results were similar for patients with and without heart failure. Compared with propensity score-matched control participants, the risk of death (adjusted HR: 1.78; 95% CI: 1.37 to 2.31) and sudden death (adjusted HR: 2.14; 95% CI: 1.11 to 4.12) was significantly higher in new digoxin users. In patients with AF taking digoxin, the risk of death was independently related to serum digoxin concentration and was highest in patients with concentrations ≥1.2 ng/ml. Initiating digoxin was independently

EvidenceUpdates2018

70. Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies

Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies 29549089 2018 03 24 1468-201X 2018 Mar 16 Heart (British Cardiac Society) Heart Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies. heartjnl-2017-312781 10.1136/heartjnl-2017-312781 Heart (...) failure (HF) often coexists in atrial fibrillation (AF) but is frequently unrecognised due to overlapping symptomatology. Furthermore, AF can cause elevated natriuretic peptide levels, impairing its diagnostic value for HF detection. We aimed to assess the prevalence of previously unknown HF in community-dwelling patients with AF, and to determine the diagnostic value of the amino-terminal pro B-type natriuretic peptide (NTproBNP) for HF screening in patients with AF. Individual participant data from four

EvidenceUpdates2018

71. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. BACKGROUND: Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in treatment guidelines for preventing stroke and systemic embolic events in people with atrial fibrillation (AF). This is an update of a Cochrane review previously published in 2013. OBJECTIVES: To assess the effectiveness and safety of treatment with factor Xa inhibitors versus (...) VKAs for preventing cerebral or systemic embolic events in people with AF. SEARCH METHODS: We searched the trials registers of the Cochrane Stroke Group and the Cochrane Heart Group (September 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (August 2017), MEDLINE (1950 to April 2017), and Embase (1980 to April 2017). We also contacted pharmaceutical companies, authors and sponsors of relevant published trials. We used outcome data from marketing authorisation applications

Cochrane2018

72. Drivers of Atrial Fibrillation: Theoretical Considerations and Practical Concerns

Drivers of Atrial Fibrillation: Theoretical Considerations and Practical Concerns 29636973 2018 11 14 2050-3369 7 1 2018 Mar Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Drivers of Atrial Fibrillation: Theoretical Considerations and Practical Concerns. 49-54 10.15420/aer.2017.40.3 Understanding the mechanisms responsible for driving AF is key to improving the procedural success for AF ablation. In this review, we look at some of the proposed drivers of AF, the disagreement (...) between experts and the challenges confronted in attempting to map AF. Defining a 'driver' is also controversial, but for the purposes of this review we will consider an AF driver to be either a focal or localised source demonstrating fast, repetitive activity that propagates outward from this source, breaking down in to disorganisation further away from its origin. Mann Ian I Imperial College Healthcare NHS TrustLondon, UK. Sandler Belinda B Imperial College Healthcare NHS TrustLondon, UK. Linton

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

73. Systematic Screening for Atrial Fibrillation in the Community: Evidence and Obstacles

Systematic Screening for Atrial Fibrillation in the Community: Evidence and Obstacles 29636971 2018 11 14 2050-3369 7 1 2018 Mar Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Systematic Screening for Atrial Fibrillation in the Community: Evidence and Obstacles. 39-42 10.15420/aer.2017.47.2 With an ageing population globally, the burden of atrial fibrillation (AF) and its consequent complication of stroke and risk of mortality will continue to increase. Although opportunistic (...) screening for AF by pulse check or ECG rhythm strip for people >65 years of age is currently recommended, data are now emerging that demonstrate the possible benefits of systematic community screening. Such screening is capable of identifying previously undiagnosed AF in 0.5-3.0 % of all those screened. The effectiveness of screening programmes will be markedly weakened by the lack of a structured downstream management pathway, making it a mandatory component in any AF screening programme

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

74. How to Prevent, Detect and Manage Complications Caused by Cryoballoon Ablation of Atrial Fibrillation

How to Prevent, Detect and Manage Complications Caused by Cryoballoon Ablation of Atrial Fibrillation 29636968 2018 11 14 2050-3369 7 1 2018 Mar Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev How to Prevent, Detect and Manage Complications Caused by Cryoballoon Ablation of Atrial Fibrillation. 18-23 10.15420/aer.2017.32.1 Atrial fibrillation is the most common cardiac arrhythmia and the prevalence is increasing every year. Patients who fail to maintain sinus rhythm with use (...) Sep;8(9):1459 20601153 Atrial fibrillation atrio-oesophageal fistula bronchial injury catheter ablation cryoablation cryoballoon dosing phrenic nerve injury Disclosure: Research, travel, and honorarium from Medtronic Inc. for Wilber Su and Richard Wu. 2018 4 12 6 0 2018 4 11 6 0 2018 4 11 6 1 ppublish 29636968 10.15420/aer.2017.32.1 PMC5889802

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

75. Authors’ Reply: Hybrid Approach for Atrial Fibrillation Ablation: the Jury is Still Out

Authors’ Reply: Hybrid Approach for Atrial Fibrillation Ablation: the Jury is Still Out 29686873 2018 11 14 2050-3369 7 1 2018 Mar Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Authors' Reply: Hybrid Approach for Atrial Fibrillation Ablation: the Jury is Still Out. 65-66 10.15420/aer.2017.7.1.L3.R3 Pearman Charles M CM Liverpool Heart and Chest Hospital, Liverpool and Manchester Academic Health Science Centre, University of Manchester Manchester, UK. Liverpool Heart

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

76. Hybrid Approach for Atrial Fibrillation Ablation: the Jury is Still Out

Hybrid Approach for Atrial Fibrillation Ablation: the Jury is Still Out 29636976 2018 11 14 2050-3369 7 1 2018 Mar Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Hybrid Approach for Atrial Fibrillation Ablation: the Jury is Still Out. 65 10.15420/aer.2017.7.1.L3 Giannopoulos Georgios G Yale School of MedicineNew Haven, CT, USA. Deftereos Spyridon S Yale School of MedicineNew Haven, CT, USA. eng Journal Article England Arrhythm Electrophysiol Rev 101637930 2050-3369 Arrhythm

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

77. Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation

Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation 29447733 2018 02 15 1558-3597 71 7 2018 Feb 20 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. 727-735 S0735-1097(17)41924-3 10.1016/j.jacc.2017.12.011 Stroke can occur after myocardial infarction (MI) in the absence of atrial fibrillation (AF). This study (...) sought to identify risk factors (excluding AF) for the occurrence of stroke and to develop a calibrated and validated stroke risk score in patients with MI and heart failure (HF) and/or systolic dysfunction. The datasets included in this pooling initiative were derived from 4 trials: CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction), OPTIMAAL (Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan), VALIANT

EvidenceUpdates2018

78. New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial

New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial 29447735 2018 03 01 1558-3597 71 7 2018 Feb 20 Journal of the American College of Cardiology J. Am. Coll. Cardiol. New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial. 739-748 S0735-1097(17)41926-7 10.1016/j.jacc.2017.12.012 There is limited information on the incidence and prognostic impact of new-onset atrial fibrillation (NOAF) following percutaneous coronary intervention (...) were analyzed according to the development of NOAF during the initial hospitalization following revascularization. Among 1,812 patients without atrial fibrillation on presentation, NOAF developed at a mean of 2.7 ± 2.5 days after revascularization in 162 patients (8.9%), including 161 of 893 (18.0%) CABG-treated patients and 1 of 919 (0.1%) PCI-treated patients (p < 0.0001). Older age, greater body mass index, and reduced left ventricular ejection fraction were independent predictors of NOAF

EvidenceUpdates2018

79. Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study

Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study 29017957 2018 02 06 1931-3543 153 2 2018 Feb Chest Chest Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study. 453-466 S0012-3692(17)32881-7 10.1016/j.chest.2017.10.001 Most data on the clinical epidemiology of atrial fibrillation (AF) come from (...) Western populations, and data for Asians are limited. We investigated the lifetime risk and projected number of AF among Asians. The annual risks of adverse events among patients with AF, time trends, and the risks compared with patients without AF were analyzed. Between 2000 and 2011, 289,559 patients aged ≥ 20 years experienced new-onset AF in Taiwan. The incidence, prevalence, and lifetime risk of AF were calculated. The risk of adverse events among patients with AF were analyzed and compared

EvidenceUpdates2018

80. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc?

Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? 29459469 2018 02 20 1524-4539 137 8 2018 Feb 20 Circulation Circulation Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA 2 DS 2 -VA Score Rather Than CHA 2 DS 2 -VASc? 832-840 10.1161/CIRCULATIONAHA.117.029081 Stroke risk in atrial fibrillation is assessed by using the CHA 2 DS 2 -VASc (...) score. Sex category (Sc, ie, female sex) confers 1 point on CHA 2 DS 2 -VASc. We hypothesized that female sex is a stroke risk modifier, rather than an overall risk factor, when added to a CHA 2 DS 2 -VA (sex-independent thromboembolism risk) score scale. Using 3 nationwide registries, we identified patients with incident nonvalvular atrial fibrillation from January 1, 1997, through December 31, 2015. Patients receiving oral anticoagulant treatment at baseline were excluded, and person-time

EvidenceUpdates2018